olaptesed pegol (NOX-A12)

Through analysis of representative clinical programs, including the systemic nucleolin-targeting aptamer AS1411, the microenvironment-modulating CXCL12 inhibitor NOX-A12, and the locally administered personalized platform AM003, this review highlights how delivery strategy, target context, and clinical deployment critically shape therapeutic outcomes. Recurrent translational barriers related to systemic exposure, tumor accessibility, regulatory pathways, and competition with established modalities are identified, together with lessons from both failed and emerging programs. Finally, we discuss practical strategies to improve clinical alignment, including human-relevant selection models, localized or combination therapies, and AI-assisted design, positioning aptamers for context-appropriate roles in future precision oncology.

Although most aptamer-based checkpoint inhibitors remain in preclinical stages, early phase clinical investigations (primarily with C-X-C motif chemokine ligand 12 (CXCL12)-targeting Spiegelmer NOX-A12 in combination settings, as well as earlier programs such as AS1411 targeting nucleolin) have demonstrated effective inhibition of immune checkpoint signaling, reactivation of T-cell function, and synergistic effects when combined with existing immunotherapies. Preclinical and early phase clinical investigations have demonstrated that aptamers can effectively inhibit immune checkpoint signaling, reactivate T-cell function, and potentiate synergistic effects when combined with existing immunotherapies. By critically evaluating current progress and identifying key translational challenges, this review provides strategic insights into the future development of aptamer-based immunotherapeutic platforms, ultimately guiding the advancement of more precise, cost-effective, and personalized cancer treatment modalities.

Important clinical successes include the results of NOX-A12 drug and data on combined drugs based on trastuzumab in patients with metastatic breast cancer. Furthermore, very high control of breast cancer brain metastases in HER-2 positive cases was demonstrated for trastuzumab-emtansine and trastuzumab-deruxtecan. The last finding indicates the perspective for aptamer targeting glioblastoma tumor cells in conjugation with emtansine or deruxtecan.

P2, N=60, Not yet recruiting, TME Pharma AG | Trial completion date: Oct 2028 --> Mar 2029 | Trial primary completion date: Oct 2027 --> Mar 2028

P1/2, N=117, Active, not recruiting, TME Pharma AG | N=27 --> 117 | Trial completion date: Dec 2024 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2028

P2, N=60, Not yet recruiting, TME Pharma AG | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Oct 2027

In a post-hoc exploratory analysis of tumor tissue, higher frequency of CXCL12+ endothelial and glioma cells was significantly associated with longer PFS under NOX-A12. Our data imply safety of NOX-A12 and its efficacy signal warrants further investigation.

Interim data of the ongoing trial confirm the previously established safety profile of NOX-A12 for combinatory treatment with bevacizumab while demonstrating improved efficacy with deeper and longer-lasting responses and a higher ORR compared to treatment with RT and NOX-A12 only.

8 In this study we aimed to address the role of CXCL12 and its inhibition by NOX-A12 (with and without immune checkpoint inhibitors, ICI) in modulating the immune landscape in mice bearing GBM...Conclusions Inhibition of CXCL12 resulted in a time-dependent array of changes in peripheral blood and tumor-bearing brains but no clear survival benefit. Whether immune-related brain edema, or insufficient activation of immune cells in TME contributed to this result will be clarified by comparing response between intracranial and flank tumor, to better understand the mechanism of immune cell trafficking and polarization mediated by CXCL12 in GBM.

Conclusions m IF of matched pre-/post-therapy tissue samples from the ongoing GLORIA trial supports the proposed modes of action of RT and NOX-A12 counteracting vasculogenesis and modulating the iTME reflected through its spatial rearrangement. This opens up the question of a targetable, compartment-specific role of CXCL12 to be further assessed.

P1/2, N=27, Active, not recruiting, TME Pharma AG | Recruiting --> Active, not recruiting

We show superior clinical efficacy of RT and NOX-A12 in patients with high frequency of CXCL12 expressing endothelial and glioma cells, suggesting the use of the EG12 score as a novel predictive biomarker for CXCL12-directed therapies in GBM. Clinical trial information: NCT04121455.